- Solve real problems with our hands-on interface
- Progress from basic puts and calls to advanced strategies
Posted April 17, 2025 at 9:45 am
The stock market had a tough outing Wednesday, as NVIDIA (NVDA) and the semiconductor stocks fell sharply on demand concerns triggered by NVIDIA’s large accounting charge related to export restrictions for China. Beyond that, the broader market struggled with Fed Chair Powell’s thoughts that tariffs are likely to drive inflation higher in the near term, that the Fed isn’t going to be hasty with policy changes, and that there is no Fed put.
President Trump is certainly struggling with the Fed chair’s views. He was adamant in a Truth Social Post that the Fed should be lowering rates now and exclaimed that Jerome Powell’s “termination cannot come fast enough!”
Separately, President Trump also took to Truth Social to proclaim that “big progress” was made yesterday in trade talks with Japan, that he had a productive call with the president of Mexico yesterday, and that he will be meeting with Italy’s prime minister today.
The market seems to like the idea of trade progress being made, but it is also cognizant that any positive views on trade matters can change in an instant. That understanding has curtailed investors’ conviction in buying efforts along with the festering concerns about earnings not living up to higher expectations.
The market has a lot to live up to right now, and it is struggling from a lack of confidence that is an offshoot of the policy uncertainty. It is trying to find some higher ground this morning, yet there are distractions in its midst, like the president calling out Fed Chair Powell, like China digging in with its retaliatory trade actions, and like this morning’s ugly FY25 earnings guidance from Dow component UnitedHealth Group (UNH).
Shares of UNH are down 20% in pre-market trading after the company said it expects FY25 adjusted EPS to be $26.00-26.50. The midpoint of that range is nearly 12% below the current consensus estimate. The warning was attributed to “heightened care activity indications in UnitedHealthcare’s Medicare Advantage businesses [and]…unanticipated changes in the profile of Optum Health members.”
The loss in UNH is why the Dow futures are in their own world right now. Currently, the S&P 500 futures are up 21 points and are trading 0.3% above fair value, the Nasdaq 100 futures are up 117 points and are trading 0.6% above fair value, and the Dow Jones Industrial Average futures are down 537 points and are trading 1.4% below fair value.
An 11% gain in Eli Lilly (LLY) after it announced positive trial results for its weight-loss drug pill and rebound action in the mega-cap space has helped offset UNH’s problems and a modest 0.8% decline in shares of American Express (AXP) after it reported better-than-expected Q1 results.
That has added to a very busy news cycle this morning, which has also included earnings reports from DR Horton (DHI), Taiwan Semiconductor Manufacturing Company (TSM), CSX Corp. (CSX), Snap-on Inc. (SNA), and a host of regional banks, as well as the ECB’s expected decision to cut its key interest rates by 25 basis points and a mixed batch of economic data.
—
Originally Posted April 17, 2025 – Mixed start expected amid UNH, trade, and economic news
Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Briefing.com and is being posted with its permission. The views expressed in this material are solely those of the author and/or Briefing.com and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Join The Conversation
For specific platform feedback and suggestions, please submit it directly to our team using these instructions.
If you have an account-specific question or concern, please reach out to Client Services.
We encourage you to look through our FAQs before posting. Your question may already be covered!